MOUNTAIN VIEW, Calif., May 30 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Laurent Claret, Ph.D., Senior Scientist, will speak to members of the pharmaceutical and biotechnology industries attending the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held at the Georgia World Congress Center in Atlanta, Georgia, June 2-6, 2006.
Dr. Claret will present in the Health Services Research Track, along with a multidisciplinary panel of speakers from industry, in a Poster Discussion Session. The title of Dr. Claret's presentation is "Model-based predictions of expected anti-tumor response and survival in Phase III studies based on Phase II data of an investigational agent." The poster discussion session will describe research from clinicians, public health researchers, and pharmaceutical scientists on how clinical trial practices and novel technologies, including quantitative modeling and simulation, are impacting the development, approval and use of therapies in oncology. Additional information can be found at www.asco.org.
"Model-based drug development continues to show value for improving the quality of drug development decisions," said Shawn M. O'Connor, President and Chief Executive Officer. Drug development in oncology can benefit from the quantitative application of drug-disease models using longitudinal data to simulate expected clinical response of new compounds, and to support critical program strategy and study design decisions. Pharsight is pleased to participate at the ASCO Annual Meeting, which serves as a leading global forum for oncology professionals dedicated to discovering and developing new cancer therapies."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Pharsight CorporationCONTACT: investors, Douglas Sherk, or Jennifer Beugelmans,+1-415-896-6820, or media, Steve DiMattia, +1-917-620-0590, all of EVCGroup for Pharsight Corporation
